• Product NameRecombinant Murine Interleukin-33
• Host SpeciesEscherichia coli.
• Purification> 98 % by SDS-PAGE and HPLC analyses.
• Biological ActivityFully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using murine D10S cells is less than 0.5 ng/ml, corresponding to a specific activity of > 2.0 x10⁶ IU/mg.
• EndotoxinLess than 1 EU/ug of rMuIL-33 as determined by LAL method.
• Alternative Names    IL-1F11, NF-HEV
• UniprotQ8BVZ5
• Gene ID77125
• Calculated MW Approximately 17.5 kDa protein containing 158 amino acid residues.
• Target Sequence SIQGTSLLTQ SPASLSTYND QSVSFVLENG CYVINVDDSG KDQEQDQVLL RYYESPCPAS QSGDGVDGKK LMVNMSPIKD TDIWLHANDK DYSVELQRGD VSPPEQAFFV LHKKSSDFVS FECKNLPGTY IGVKDNQLAL VEEKDESCNN IMFKLSKI
• Formulation Lyophilized from a 0.2 μm filtered solution in PBS, and 1 mM EDTA.
• Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 ˚C as supplied.- 1 month, 2 to 8 ˚C under sterile conditions after reconstitution.- 3 months, -20 to -70 ˚C under sterile conditions after reconstitution.

IL-33 is a number of IL-1 superfamily, secreted by high endothelial venules at high levels, which is found in tonsils, peyer patches and mesenteric lymph nodes, but not in placenta. It elicits its biological effects by interacting with IL1RL1/ST2 and its stimulation recruits MYD88, IRAK1, IRAK4, and TRAF6, followed by phosphorylation of MAPK3/ERK1 and/or MAPK1/ERK2, MAPK14, and MAPK8. IL-33 induces production of TH2 cell related cytokines, including IL-4, IL-5 and IL-13, and exerts multiple inflammation related bioactivities. Mature IL-33 share approximately 55 % and 90 % a.a. sequence identity with human and rat IL-33 respectively.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting